Benchmark Maintains Buy on Agilon Health, Lowers Price Target to $95
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Benchmark analyst Bill Sutherland maintains Agilon Health (NYSE:AGL) with a Buy and lowers the price target from $13 to $95.
Benchmark analyst Bill Sutherland maintains Agilon Health (NYSE:AGL) with a Buy and lowers the price target from $13 to $95.